AIM Stock Forecast: AIM ImmunoTech, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.11
−4.50% on the day

The median 12-month analyst price target for AIM ImmunoTech, Inc. is $4.25. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 33 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$4.8M
Ticker Nerd rank
33/ 100
Median analyst target
$4.25
Analysts covering
2
Revenue$22K+37.5% y/y
Operating income−$2.2M
Net income−$3.0M
Free cash flow−$2.8M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−18.1%
1M
−32.6%
YTD
−89.5%
1Y
−90.9%
From 52W high
−92.6%
From 52W low
0.0%
$0.11
$1.54
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores AIM ImmunoTech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
33/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
73
Growth
59
Issuance
45
Accruals
43
Volatility
39
Quality
16
Value
11
Momentum
5

Revisions (73): Analysts have, on balance, been raising their forecasts.

Momentum (5): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AIM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AIM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26AIMHigh $7.00Median $4.25Low $1.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$1.50
Low
$4.25
Median
$7.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026Ascendiant CapitalMaintainsBuy—
1 June 2026Ascendiant CapitalMaintainsBuy—
10 Apr 2026Ascendiant CapitalMaintainsBuy—
8 Dec 2025Ascendiant CapitalMaintainsBuy—
3 Oct 2025Ascendiant CapitalMaintainsBuy—
10 Dec 2024Ascendiant CapitalMaintainsBuy—
22 Oct 2024Maxim GroupMaintainsBuy—
3 Sept 2024Ascendiant CapitalMaintainsBuy—
10 Oct 2019Maxim GroupUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AIM.

Market Radar

This page is one stock. Monday covers all of them.

AIM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AIM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, AIM ImmunoTech, Inc. returned −90.9% against +6.9% for the S&P 500, dividends included.

AIM vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26AIMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AIM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
47.2×

Cheaper than 5% of US stocks

Price / book
0.9×

Cheaper than 74% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
81.8%

Higher than 92% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−2382.3%

Higher than 1% of US stocks

Return on assets
−82.6%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AIM ImmunoTech, Inc. has a market value of $4.8M.

  • Revenue in the twelve months to 31 Mar 2026: $94K. The latest quarter grew 37.5% year on year.

  • Net income over the same four quarters: −$13.3M, a −14123.4% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$11.7M.

  • Shares outstanding: 39.9M.

  • AIM ImmunoTech, Inc. employs 19 people — $5K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

AIM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AIMAIM ImmunoTech, Inc.$4.8M33
SNTISenti Biosciences Holdings, Inc.$4.6M33
PCSAProcessa Pharmaceuticals, Inc.$4.4M21
PULMPulmatrix, Inc.$4.6M47
CDIOCardio Diagnostics Holdings, Inc.$4.7M20
NIKINiki Biosolutions, Inc.$4.9M9
CRISCuris, Inc.$4.1M35

Take a look at AIM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own AIM ImmunoTech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about AIM

What is the AIM stock price forecast for 2026-2027?

The median 12-month analyst price target for AIM ImmunoTech, Inc. is $4.25, with estimates ranging from $1.5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AIM stock a buy right now?

Of the 2 analysts covering AIM ImmunoTech, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AIM ImmunoTech, Inc. 33 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AIM?

As at 21 Nov 2026, AIM ImmunoTech, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (73 of 100).

Will AIM stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $4.25, and Ticker Nerd's factor model ranks AIM ImmunoTech, Inc. 33 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AIM stock forecast for 2030?

No analyst covering AIM ImmunoTech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $7 over the next 12 months.

How has AIM stock performed over the past year?

AIM ImmunoTech, Inc. returned -90.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AIM ImmunoTech, Inc. do?

AIM ImmunoTech Inc. is a biotechnology company focused on developing immuno-modulating therapeutics for cancer, viral diseases, and immune-related disorders. Its current portfolio centers on Ampligen, an investigational double-stranded RNA therapy being evaluated in clinical studies for oncology and selected viral and immune conditions, and Alferon N Injection, a natural-source interferon product used for specific approved indications.

Company

About AIM ImmunoTech, Inc.

AIM ImmunoTech Inc. is a biotechnology company focused on developing immuno-modulating therapeutics for cancer, viral diseases, and immune-related disorders. Its current portfolio centers on Ampligen, an investigational double-stranded RNA therapy being evaluated in clinical studies for oncology and selected viral and immune conditions, and Alferon N Injection, a natural-source interferon product used for specific approved indications. The company works across preclinical and clinical research, with an emphasis on immune system activation, antiviral defense, and combination approaches for difficult-to-treat diseases. AIM ImmunoTech serves the biopharmaceutical sector by advancing specialized therapies that target areas with limited treatment options, making it a recognized participant in immunotherapy and antiviral drug development.

CEO Mr. Thomas K. Equels Esq., J.D., M.S. · 19 employees · United States · https://aimimmuno.com